CD47 and Splenomegaly: In addition, and as expected, benchmark experiments revealed that TAX2 peptide does not recapitulate adverse events relative to anti-CD47 therapies, especially regarding splenomegaly, hematology, red blood cells count, necrosis, hemoglobin concentration, platelets count and leukocyte count (Supplementary Materials Figure S2).